PA8616101A1 - Forma de presentacion del naproxeno sodico - Google Patents

Forma de presentacion del naproxeno sodico

Info

Publication number
PA8616101A1
PA8616101A1 PA20048616101A PA8616101A PA8616101A1 PA 8616101 A1 PA8616101 A1 PA 8616101A1 PA 20048616101 A PA20048616101 A PA 20048616101A PA 8616101 A PA8616101 A PA 8616101A PA 8616101 A1 PA8616101 A1 PA 8616101A1
Authority
PA
Panama
Prior art keywords
nucleus
weight
sodium
presentation
sodium naproxen
Prior art date
Application number
PA20048616101A
Other languages
English (en)
Inventor
Peter Gruber
Martin Siegmund
Original Assignee
Bayer Consumer Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8616101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Consumer Care Ag filed Critical Bayer Consumer Care Ag
Publication of PA8616101A1 publication Critical patent/PA8616101A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

UN COMPRIMIDO NO EFERVESCENTE DE NAPROXENO SODICO, QUE CONSTA DE UN NUCLEO DE COMPRIMIDO Y SI SE DESEA DE UN REVESTIMIENTO DE AZUCAR O DE UNA PELICULA, DONDE EL NUCLEO DEL COMPRIMIDO, RESPECTO AL PESO DEL NUCLEO DEL COMPRIMIDO, SE COMPONE DE UN 30 HASTA DE UN 99% EN PESO DE NAPROXENO SODICO Y DE UN 70 HASTA DE UN 1% EN PESO DE COMPONENTE DE MATERIA AUXILIAR, QUE INCLUYE COMO MINIMO UNA SUSTANCIA AUXILIAR BASICA, POSEE UNA DUREZA SUFICIENTE, ES COMPARATIVAMENTE PEQUEÑO Y CONDUCE A UN AUMENTO DEL NIVEL DE SANGRE ESPECIALMENTE RAPIDO Y CON ELLO A UNA ACCION ANALGESICA.
PA20048616101A 2003-10-30 2004-10-28 Forma de presentacion del naproxeno sodico PA8616101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH18482003 2003-10-30

Publications (1)

Publication Number Publication Date
PA8616101A1 true PA8616101A1 (es) 2005-08-04

Family

ID=34529359

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048616101A PA8616101A1 (es) 2003-10-30 2004-10-28 Forma de presentacion del naproxeno sodico

Country Status (15)

Country Link
US (1) US20070134317A1 (es)
EP (1) EP1684728B1 (es)
JP (1) JP2007509862A (es)
AR (1) AR046213A1 (es)
AT (1) ATE442840T1 (es)
BR (1) BRPI0415624A (es)
CA (1) CA2543709A1 (es)
CR (1) CR8406A (es)
DE (1) DE602004023220D1 (es)
EC (1) ECSP066587A (es)
ES (1) ES2333332T3 (es)
PA (1) PA8616101A1 (es)
PE (1) PE20050445A1 (es)
UY (1) UY28583A1 (es)
WO (1) WO2005041938A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
AU2006226293B2 (en) 2005-03-22 2011-04-07 Losan Pharma Gmbh Solubilized ibuprofen
EP3263117A1 (en) 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
EP3364955B1 (en) * 2015-10-09 2022-04-20 RB Health (US) LLC Pharmaceutical formulation
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬
US11779541B2 (en) 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US5034416A (en) * 1988-01-19 1991-07-23 Smith Walton J Carboxylic acid compositions
US5358717A (en) * 1989-12-22 1994-10-25 Syntex (U.S.A.) Inc. Directly-compressible naproxen or naproxen sodium compositions
PT96229B (pt) * 1989-12-22 1998-06-30 Syntex Pharma Int Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
JPH10298072A (ja) * 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020192161A1 (en) * 2001-04-10 2002-12-19 Fahkreddin Jamali Animal model for evaluating analgesics
WO2002083110A2 (en) * 2001-04-10 2002-10-24 Zagros Pharma, Inc. Animal model for evaluating analgesics

Also Published As

Publication number Publication date
PE20050445A1 (es) 2005-06-18
AR046213A1 (es) 2005-11-30
CR8406A (es) 2008-04-25
ECSP066587A (es) 2006-10-17
JP2007509862A (ja) 2007-04-19
CA2543709A1 (en) 2005-05-12
EP1684728A1 (en) 2006-08-02
ATE442840T1 (de) 2009-10-15
UY28583A1 (es) 2005-05-31
WO2005041938A1 (en) 2005-05-12
BRPI0415624A (pt) 2006-12-12
DE602004023220D1 (de) 2009-10-29
US20070134317A1 (en) 2007-06-14
ES2333332T3 (es) 2010-02-19
EP1684728B1 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
CR8406A (es) Forma de administracion del naproxeno sodico
UY29853A1 (es) Derivados de diacilindazol como inhibidores de lipasas y fosfolipasas-
GT200600200A (es) Composicion farmaceutica que contienen gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
CL2011002781A1 (es) Compuestos (e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol y (r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol; composicion farmaceutica que los comprende; y uso en el tratamiento del cancer.
CR20160203A (es) Inhibidores de tirosina cinasa de bruton
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
UY28735A1 (es) Derivados de indazol como inhibidores de la lipasa sensible a hormonas
AR053803A1 (es) Uso de acido pinolenico
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY29872A1 (es) Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas
AR052190A1 (es) Uso de clorantes de cianina para el diagnostico de enfermedades proliferativas
AR054060A1 (es) Forma de dosificacion farmaceutica unitaria
SG160415A1 (en) Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
PA8809601A1 (es) Combinación anti-retroviral
CL2008003284A1 (es) Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras.
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
UY29594A1 (es) Derivados de benzotiazol-2-ona como inhibidores de lipasas y fosfolipasas
CL2011002270S1 (es) Unidad aritmetica y de control para videojuego o similar de cuerpo paralelepipedico rectangular con surco perimetral que la cara frontal en su parte posterior inferior, comprende 4 ranuras de circunferencias concentricas ubicadas una al lado de otra. (divisional solictud 1642-09)
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
AR077612A1 (es) Dispositivo indicador para un distribuidor de dosis de medicamentos asi como su uso
BRPI0507399A (pt) combinação de voriconazol e um inibidor cyp2c19 antifungo,composição farmacêutica, kit, forma de dosagem unitária e uso dos mesmos
PA8802001A1 (es) Combinación antiretroviral novedosa